Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 1/2 1

Status

Recruiting 4Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Colorectal Neoplasms 5Esophageal Squamous Cell Carcinoma 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Esophageal Neoplasms 3Stomach Neoplasms 2Neoplasms 2Leukemia, Biphenotypic, Acute 2Burkitt Lymphoma 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Rectal Diseases 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Endometrial Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Colonic Neoplasms 1Colonic Diseases 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Bevacizumab 119Fluorouracil 91Leucovorin 83Cetuximab 83Oxaliplatin 80pembrolizumab 70Irinotecan 67Nivolumab 46Capecitabine 43Specimen Handling 40regorafenib 30Folfox protocol 29trifluridine tipiracil drug combination 28Magnetic Resonance Spectroscopy 27Biopsy 27Panitumumab 26Standard of Care 25HMPL-013 25IFL protocol 21Gemcitabine 20Blood Specimen Collection 19atezolizumab 18Trifluridine 18Cisplatin 18tislelizumab 17balstilimab 16Colonoscopy 16Carboplatin 16encorafenib 15Paclitaxel 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Colorectal Neoplasms × Levoleucovorin × 1 year × Clear all
NCT06662786 2026-06-05

OrigAMI-2

Janssen Research & Development, LLC

Phase 3 Recruiting
1,000 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06750094 2026-06-05

OrigAMI-3

Janssen Research & Development, LLC

Phase 3 Recruiting
700 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05253651 2026-06-04

MOUNTAINEER-03

Seagen Inc.

Phase 3 Recruiting
400 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06428409 2026-01-22

MK-9999-02A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
220 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Colorectal Neoplasms

NCT04607421 2025-08-14

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Pfizer

Phase 3 Active not recruiting
831 enrolled 2 FDA
Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡